Consortium Collection Publications

Publications Arising from Consortium Collection Studies

  1. Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc Natl Acad Sci USA 2006;103(19):7482-7487.
  2. Aberg K, Saetre P, Lindholm E, Ekholm B, Pettersson U, Adolfsson R, Jazin E. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am J Med Genet B Neuropsychiatr Genet 2006;141B(1):84-90.
  3. Agam G, Shaltiel G, Kozlovsky N, Shimon H, Belmaker RH. Corrigendum to “Lithium inhibitable enzymes in postmortem brain of bipolar patients.” J Psychiatr Res 2003;37(5):433-442. J Psychiatr Res 2003;37(6):557.
  4. Agam G, Shaltiel G, Kozlovsky N, Shimon H, Belmaker RH. Lithium inhibitable enzymes in postmortem brain of bipolar patients. J Psychiatr Res 2003;37(5):433-442.
  5. Agis-Balboa RC, Guidotti A, Pinna G. 5∝-reductase type I expression is a downregulated in the prefrontal cortex/Brodmann’s area 9 (BA9) of depressed patients. Psychopharmacology (Berl). 2014; 231: 3569-80.
  6. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, Young TA, Bullard J, Yokoe H, Webster MJ, Knable MB, Brockman JA. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 2005;58(2):85-96.
  7. Altshuler LL, Abulseoud OA, Foland-Ross L, Bartzokis G, Chang S, Mintz J, Hellemann G, Vinters HV. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 2010;12(5):541-549.
  8. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochrondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67(4):360-368.
  9. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004;77(6):858-866.
  10. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 2005;10(3):309-322.
  11. Bader V, Tompps L, Trossbach SV, Bradshaw NJ, Prikulis I, Leliveld SR, Lin CY, Ishizuka K, Sawa A, Ramos A, Rosa I, García Á, Requena JR, Hipolito M, Rai N, Nwulia E, Henning U, Ferrea S, Luckhaus C, Ekelund J, Veijola J, Järvelin MR, Hennah W, Korth C. Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits. Hum Mol Genet. 2012;21(20):4406-4418.
  12. Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr Res 2009;112(1-3):54-64.
  13. Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2000;24(6):881-888.
  14. Beasley C, Cotter D, Everall I. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res 2002;58(1):63-67.
  15. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, Lovestone S, Anderton B, Everall I. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001;302(2-3):117-120.
  16. Beasley CL, Chana G, Honavar M, Landau S, Everall IP, Cotter D. Evidence for altered neuronal organisation within the planum temporale in major psychiatric disorders. Schizophr Res 2005;73(1):69-78.
  17. Beasley CL, Cotter DR, Everall IP. Density and distribution of white matter neurons in schizophrenia, bipolar disorder and major depressive disorder: no evidence for abnormalities of neuronal migration. Mol Psychiatry 2002;7(6):564-570.
  18. Beasley CL, Honavar M, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the superior temporal white matter in schizophrenia, major depressive disorder and bipolar disorder. Schizophr Res 2009;115(2-3): 156-162.
  19. Beasley CL, Honer WG, Bergmann K, Falkai P, Lutjohann D, Bayer TA. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord 2005;7(5):449-455.
  20. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in schizophrenia, bipolar disorder and major depressive disorder: evidence for disease-associated changes. Proteomics 2006;6(11):3414-3425.
  21. Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002;52(7):708-715.
  22. Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 2009;14(6):601-613.
  23. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007;90(1-3):41-51.
  24. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007;32(9):1888-1902.
  25. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008;33(9):2175-2186.
  26. Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochrondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 2008;3(11):e3676.
  27. Ben-Shachar D, Karry R. Sp1 expression is disrupted in schizophrenia: a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS ONE 2007;2(9):e817.
  28. Bezchlibnyk YB, Sun X, Wang JF, MacQueen GM, McEwen BS, Young LT. Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. J Psychiatry Neurosci 2007;32(3):203-210.
  29. Bezchlibnyk YB, Wang JF, McQueen GM, Young LT. Gene expression differences in bipolar disorder revealed by cDNA array analysis of postmortem frontal cortex. J Neurochem 2001;79(4):826-834.
  30. Bezchlibnyk YB, Xu L. Wang JF, Young LT. Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res 2007;1147:213-7.
  31. Bown C, Wang JF, MacQueen G, Young LT. Increased temporal cortex ER stress proteins in depressed subjects who died by suicide. Neuropsychopharmacology 2000;22(3):327-332.
  32. Brauch RA, Adnan El-Masri M, Parker JC Jr, El-Mallakh RS. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J Affect Disord 2006;91(1):87-90.
  33. Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, O’Donovan MC. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005;14(14):1947-1954.
  34. Bundo M, Toyoshima M, Okada Y, Akamatsu W, Ueda J, Nemoto-Miyauchi T, SUnaga F, Toritsuka M, Ikawa D, Kakita A, Kato M, Kasai K, Kishimoto T, Nawa H, Okana H, Yoshikawa T, Kato T, Iwamoto K. Increased L1 retrotransposition in the neuronal genome in schizophrenia. Neuron 2014;81(2):306-313.
  35. Burmistrova OA, Goltsov AY, Abramova LI, Kaleda VG, Orlova VA, Rogaev EI. MicroRNA in schizophrenia: genetic and expression analysis of miR-130b (22q11). Biochemistry (Mosc.) 2007;72(5):578-582.
  36. Burnet PW, Harrison, PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 2000;47(1):80-83.
  37. Byne W, Tatusov A, Yiannoulos G, Vong GS, Marcus S. Effects of mental illness and aging in two thalamic nuclei. Schizophr Res 2008;106(2-3):172-181.
  38. Caberlotto L, Hurd YL. Neuropeptide Y Y1 and Y2 receptor mRNA expression in the prefrontal cortex of psychiatric subjects: relationship of Ysubtype to suicidal behavior. Neuropsychopharmacology 2001;25(1):91-97.
  39. Caberlotto L, Hurd YL. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 1999;10(8):1747-1750.
  40. Carletti R, Corsi M, Melotto S, Caberlotto L. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci 2005;21(6):1712-1718.
  41. Cabrera-Mendoza B., de Anda-Jáuregui G., Nicolini, H., & Fresno, C. . A meta-study on transcription factor networks in the suicidal brain. Journal of psychiatric research, 2021;136, 23–31.
  42. Catts VS, Weickert CS. Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. PLoS ONE 2012;7(4):e35511.
  43. Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 2003;53(12):1086-1098.
  44. Chana G, Landau S, Everall I, Cotter D. Glial cell number and nuclear size in the mediodorsal thalamic nucleus (MDNT) in schizophrenia [letter]. Schizophr Res 2008;102(1-3):344-345.
  45. Chang H, Hoshina N, Zhang C, et al. The protocadherin 17 gene affects cognition, personality, amygdala structure and function, synapse development and risk of major mood disorders. 2018. Molecular Psychiatry. 23: 400-412.
  46. Chase KA, Gavin DP, Guidotti A, Sharma RP. Histone methylation at H3K9: evidence for a restrictive epigenome in schizophrenia. Schizophr Res 2013;149(1-3):15-20.
  47. Che Y, Wang JF, Shao L, Young, LT. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010;35(5):296-302.
  48. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50(4):260-265.
  49. Chen C, Cheng L, Grennan K, Pibiri F, Zhang C, Badner JA; Members of the Bipolar Disorder Genome Study (BiGS) Consortium, Gershon ES, Liu C. Two gene co-expression modules differentiate psychotics and controls. Mol Psychiatry 2013;18(12):1308-1314.
  1. Chen C, Meng Q, Xia Y, et al. The transcription factor POU3F2 regulates a gene coexpression network in brain tissue from patients with psychiatric disorders. Science Translational Medicine 2018 Dec 19;10(472). pii: eaat8178. doi: 10.1126/scitranslmed.aat8178. Epub 2018 Dec 13.
  2. Chen H, Wang N, Zhao X, et al. Gene espression in bipolar disorder postmortem brains.Bipolar Disord. 2013. 13: 177-187.
  3. Choi J, Bodenstein DF, Geraci J, Andreazza AC. Evaluation of postmortem microarray data in bipolar disorder using traditional data comparison and artificial intelligence reveals novel gene targets. J Psychiatr Res. 2021 Oct;142:328-336.
  4. Chong VZ, Thompson M, Beltaifa S, Webster MJ, Law AJ, Weickert CS. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res 2008;100(1-3):270-280.
  5. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. J Hum Genet 2009;54(11):665-675.
  6. Clinton SM, Meador-Woodruff JH. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 2004;29(7):1353-1362.
  7. Comte I, Kotagiri P, Szele FG. Regional differences in human ependymal and subventricular zone cytoarchitecture are unchanged in neuropsychiatric disease. Dev Neurosci 2012;34(4):299-309.
  8. Conejero-Goldberg C, Torrey EF, Yolken RH. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr Res 2003;60(1):65-69.
  9. Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord 2005;7(4):358-369.
  10. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, Everall I. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002;51(5):377-386.
  11. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002;12(4):386-394.
  12. Cotter D, Mackay D, Frangou S, Hudson L, Landau S. Cell density and cortical thickness in Heschl’s gyrus in schizophrenia, major depression and bipolar disorder. Br J Psychiatry 2004;185:258-259.
  13. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001;58(6):545-553.
  14. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001;55(5):585-595.
  15. Cottrell JR, Levenson JM, Kim SH, Gibson HE, Richardson KA, Sivula M, Li B, Ashford CJ, Heindl KA, Babcock RJ, Rose DM, Hempel CM, Wiig KA, Laeng P, Levin ME, Ryan TA, Gerber DJ. Working memory impairment in calcineurin knock-out mice is associated with alterations in synaptic vesicle cycling and disruption of high-frequency synaptic and network activity in prefrontal cortex. J Neurosci 2013;33(27):10938-10949.
  16. Damadzic R, Bigelow LB, Krimer LS, Goldenson DA, Saunders RC, Kleinman JE, Herman MM. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res Bull 2001;55(5):611-618.
  17. Damadzic R, Shuangshoti S, Giblen G, Herman MM. Neuritic pathology is lacking in the entorhinal cortex, subiculum and hippocampus in middle-aged adults with schizophrenia, bipolar disorder or unipolar depression. Acta Neuropathol 2002;103(5):488-494.
  18. Darby MM, Yolken RH, Sabunciyan S. Consistently altered expression of gene sets in postmortem brains of individuals with major psychiatric disorders.Transl Psychiatry. 2016 Sep 13;6(9):e890. doi: 10.1038/tp.2016.173
  19. Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F, Kalidindi S, Picchioni M, Kravariti E, Toulopoulou T, Murray RM, Mill J. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 2011;20(24):4786-4796.
  20. Demptster EL, Mill J, Craig IW, Collier DA. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med Genet 2006;7:10.
  21. Dong E, Gavin DP, Chen Y, Davis J. Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Transl Psychiatry 2012;2:e159.
  22. Dowlatshahi D, MacQueen G, Wang JF, Chen B, Young LT. Increased hippocampal supragranular Timm staining in subjects with bipolar disorder. Neuroreport 2000;11(17):3775-3778.
  23. Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT. G protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 1999;73(3):1121-1126.
  24. Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression [letter]. Lancet 1998;352(9142):1754-1755.
  25. Dunham JS, Deakin JF, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009;43(14):1175-1184.
  26. Eastwood SL, Harrison PJ. Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Mol Psychiatry 2000;5(4):425-432.
  27. Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders: a review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 2001;55(5):569-578.
  28. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004;36(2):131-137.
  29. Emamian ES, Karayiorgou M, Gogos JA. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J Neurosci 2004;24(7):1561-1564.
  30. Farmer R, Burbano SD, Patel NS, Sarmiento A, Smith AJ, Kelly MP. Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. Cell Signal. 2020;70:109592. 
  31. Fatemi H, Earle JA, Stary JM, Lee S, Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. NeuroReport 2001;12(15):3257-3262.
  32. Fatemi SH, Earle JA, McMenomy T. Reduction in reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 2000;5(6):654-663.
  33. Fatemi SH, Folsom T, Thuras PD. Deficits in GABAreceptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res 2011;128(1-3):37-43.
  34. Fatemi SH, Folsom TD, Reutiman TJ, Vazquez G. Phosphodiesterase signaling system is disrupted in the cerebella of subjects with schizophrenia, bipolar disorder, and major depression [letter]. Schizophr Res 2010;119(1-3):266-267.
  35. Fatemi SH, Folsom TD, Rooney RJ, Thuras PD. mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 2013;3:e271.
  36. Fatemi SH, Folsom TD, Rooney RJ, Thuras, PD. Expression of GABAA α2-, β1- and ε-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder. Transl Psychiatry 2013;3:e303.
  37. Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga SA, Conti M, Menniti FS. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 2008;101(1-3):36-49.
  38. Fatemi SH, Kneeland RE, Liesch SB, Folsom TD. Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr Res 2010;124:246-247. 
  39. Fatemi SH, Laurence JA, Araghi-Niknam M, Stary JM, Schulz SC, Lee S, Gottesman II. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 2004;69(2-3):317-323.
  40. Fatemi SH, Reutiman TJ, Folsom TD, Lee S. Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder. Psychiatr Genet 2008;18(6):282-288.
  41. Fatemi SH, Stary JM, Earle JA, Araghi-Niknam M, Eagan E. GABAergic dysfunction in schizophrenia and mood disorders reflected by decreased levels of glutamic acid decarboxylase and 67 kDa and reelin proteins in cerebellum. Schizophr Res 2005;72(2-3):109-122.
  42. Fatemi-Bani A, Howe A, Zai C. Differential allelic expression of HTR1B in suicide victims: genetic and epigenetic effect of the cis-acting variants. Neuropsychobiology. 2016; 74: 144-149.
  43. Folsom TD, Thuras PD, Fatemi SH. Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders. Schizphr Res 2015;165:201-211. 
  44. Foster R, Kandanearatchi A, Beasley C, Williams B, Khan N, Fagerhol MK, Everall IP. Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process? Eur J Neurosci 2006;24(12):3561-3566.
  45. Frajman A, Maggio N, Muler I, Haroutunian V, Katsel P, Yitzhaky A, Weiser M, Hertzberg L. Gene expression meta-analysis reveals the down-regulation of three GABA receptor subunits in the superior temporal gyrus of patients with schizophrenia. Schizophr Res. 2020;220:29-37. 
  46. Frazee AC, Sabunciyan S, Hansen KD, Irizarry RD, Leek JT. Differential expression analysis of RNA-seq data at single-base resolution. Biostatistics 2014;15(3):413-426.
  47. Fujii T, Hattori K, Miyakawa T, Ohashi Y, Sato H, Kunugi H. Metabolic profile alterations in the postmortem brains of patients with schizophrenia using capillary electrophoresis-mass spectrometry. Schizophr Res 2017; 183: 70-74.
  48. Fuke S, Kametani M, Kato T. Quantitative analysis of the 4977-bp common deletion of mitochondrial DNA in postmortem frontal cortex from patients with bipolar disorder and schizophrenia. Neurosci Lett 2008;439(2):173-177.
  49. Gabriele JP, Chong VZ, Pontoriero GF, Mishra RK. Decreased expression of a 40-kDa catecholamine-regulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium. Schizophr Res 2005;74(1):111-119.
  50. Gamazon ER, Badner JA, Cheng L, Zhang C, Zhang D, Cox NJ, Gershon ES, Kelsoe JR, Greenwood TA, Nievergelt CM, Chen C, McKinney R, Shilling PD, Schork NJ, Smith EN, Bloss CS, Nurnberger JI, Edenberg HJ, Foroud T, Koller DL, Scheftner WA, Coryell W, Rice J, Lawson WB, Nwulia EA, Hipolito M, Byerley W, McMahon FJ, Schulze TG, Berrettini WH, Potash JB, Zandi PP, Mahon PB, McInnis MG, Zöllner S, Zhang P, Craig DW, Szelinger S, Barrett TB, Liu C. Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry 2013;18(3):340-346.
  51. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 2006;70(3):221-227.
  52. Gavin DP, Sharma RP, Chase KA, Matrisciano F, Dong E, Guidotti A. Growth arrest and DNA-damage-inducible, beta (GADD45B)-mediated DNA demethylation in major psychosis. Neuropsychopharmacology 2012;37(2):531-542.
  53. Gawryluk JW, Wang JF, Andreazza AC, et al. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. 2011. Int J Neuropsychophamacol.
  54. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011;14(1):123-130.
  55. Gershon ES, Grennan K, Busnello J, Badner JA, Ovsiew F, Memon S, Alliey-Rodriguez N, Cooper J, Romanos B, Liu C. A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain. Mol Psychiatry 2014;19(8):890-894.
  56. Gilabert-Juan J, Varea E, Guidaro R, Blasco-Ibáñez JM, Crespo C, Nácher J.. Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients. Neurosci Lett 2012;530(1):97-102.
  57. Gilmore JH, Bouldin TW. Analysis of ependymal abnormalities in subjects with schizophrenia, bipolar disorder, and depression. Schizophr Res 2002;57(2-3):267-271.
  58. Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and Dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res 2010;118(1-3):292-299.
  59. Goldstein I, Levy T, Galili D, Ovadia H, Yirmiya R, Rosen H, Lichstein D. Involvement of Na+, K+-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry 2006;60(5):491-499.
  60. Gottfried Y, Rotem A, Klein E, Larisch S. The pro-apoptotic ARTS/Sept4 protein is significantly reduced in post-mortem brains from schizophrenic patients. Schizophr Res 2007;96(1-3):257-266.
  61. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, Costa E. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 2005;102(26):9341-9346.
  62. Greene C, Hanley N, Campbell M. Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders. Transl Psychiatry. 2020; 10(1):373.
  63. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJM, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011;36(7):1092-1096.
  64. Guidotti A, Auta J, Davis JM, DiGiorgi Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000;57(11):1061-1069.
  65. Guidotti A, Dong E, Gavin DP, Veldic M, Zhao W, Bhaumik DK, Pandey SC, Grayson DR. DNA methylation/demethylation network expression in psychotic patients with a history of alcohol abuse. Alcohol Clin Res 2013;37(3):417-24.
  66. Guidotti A, Ruzicka W, Grayson DR, Veldic M, Pinna G, Davis JM, Costa E. S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport 2007;18(1):57-60.
  67. Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP, Pomper MG. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res 2008;99(1-3):324–332.
  68. Guilfoyle DN, Helpern JA, Lim KO. Diffusion tensor imaging in fixed brain tissue at 7.0 T. NMR Biomed 2003;16(2):77-81.
  69. Hagihara H, Catts VS, Katayama Y, et al. Decreased brain pH as a shared endophenotype of psychiatric disorders. Neuropsychopharmacology. 2018; 43: 459-468.
  70. Hamazaki K, Hamazaki T, Inadera H. Abnormalities in the fatty acid composition of the postmortem entorhinal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder. Psychiatry Res. 2013;210(1):346-350.
  71. Hamazaki K, Hamazaki T, Inadera H. Fatty acid composition in the postmortem amygdala of patients with schizophrenia, bipolar disorder, and major depressive disorder. J Psychiatr Res 2012;46(8):1024-1028.
  72. Harrison PJ, Laatikainen LM, Tunbridge EM, Eastwood SL. Human brain weight is correlated with expression of the ‘housekeeping genes’ beta-2-microglobulin (β2M) and TATA-binding protein (TBP). Neuropathol Appl Neurobiol 2010;36(6):498-504.
  73. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62(11):1310-1316.
  74. Hattori K, Tanaka H, Wakabayashi C, Yamamoto N, Uchiyama H, Teraishi T, Hori H, Arima K, Kunugi H. Expression of Ca(2+)-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1738-1743.
  75. Hayashi Y, Nihonmatsu-Kikuchi N, Hisanaga S, Yu XJ, Tatebayashi Y. Neuropathological similarities and differences between schizophrenia and bipolar disorder: A flow cytometric postmortem brain study. PLoS One 2012;7(3):e33019.
  76. Hayashi Y, Nihonmatsu-Kikuchi N, Yu X, Ishimoto K, Hisanaga SI, Tatebayashi Y. A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder [letter]. Mol Psychiatry 2011;16(12):1156–1158.
  77. Haybaeck J, Postruznik M, Miller CL, Dulay JR, Llenos IC, Weis S. Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Neuropsychiatr Dis Treat 2015;11:279-289.
  78. Helmkamp CE, Bigelow LB, Paltan-Ortiz JD, Torrey EF, Kleinman JE, Herman MM. Evaluation of superior vermal Purkinje cell placement in mental illness. Biol Psychiatry 1999;45(10):1370–1375.
  79. Herringa RJ, Roseboom PH, Kalin NH. Decreased amygdala CRF-binding protein mRNA in post-mortem tissue from male but not female bipolar and schizophrenic subjects. Neuropsychopharmacology 2006;31(8):1822-1831.
  80. Hertzberg L, Maggio N, Muler I, Yitzhaky A, Majer M, Haroutunian V, Zuk O, Katsel P, Domany E, Weiser M. Comprehensive Gene Expression Analysis Detects Global Reduction of Proteasome Subunits in Schizophrenia. Schizophr Bull. 2021;47(3):785-795.
  81. Hess JL1 Tylee DS, Barve R, de Jong S, Ophoff RA, Kumarasinghe N, Tooney P, Schall U, Gardiner E, Beveridge NJ, Scott RJ, Yasawardene S, Perera A, Mendis J, Carr V, Kelly B, Cairns M; , Tsuang MT, Glatt SJ. Transcriptome-wide mega-analyses reveal joint dysregulation of immunologic genes and transcription regulators in brain and blood in schizophrenia.Schizophr Res. 2016 Oct;176(2-3):114-124. doi: 10.1016/j.schres.2016.07.006.
  82. Hobbs JA. Detection of adeno-associated virus 2 and parvovirus B19 in the human dorsolateral prefrontal cortex. J Neurovirol 2006;12(3):190-199.
  83. Hodes A, Rosen, H, Cohen-Ben A, Lichtstein D. J Psychiatr Res. 2019. Na+, K+-ATPase α3 isoform in frontal cortex GABAergic neurons in psychiatric diseases Aug;115:21-28. doi: 10.1016/j.jpsychires.2019.04.014. Epub 2019 Apr 24.
  84. Hurd YL. Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol Psychiatry 2002;7(1):75-81.
  85. Hwang Y, Kim J, Shin J-Y, et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry. 2013. e321; doi:10.1038/tp.2013.94.
  86. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, Kato T. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 2005;25(22):5376-5381.
  87. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004;9(4):406-416.
  88. Iwamoto K, Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett 2003;346(3):169-172.
  89. Jackson KJ, Fanous AH, Chen J, Kendler KS, Chen X. Variants in the 15q25 gene cluster are associated with risk for schizophrenia and bipolar disorder. Psychiatr Genet 2013;23(1):20-28.
  90. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 2000;48(7):641-650.
  91. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004;161(1):109-115.
  92. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J Neurosci Methods 1997;77(1):83-92.
  93. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 2000;5(2):142-149.
  94. Jurata LW, Bukhman YV, Charles V, Capriglione F, Bullard J, Lemire AL, Mohammed A, Pham Q, Laeng P, Brockman JA, Altar CA. Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. J Neurosci Methods 2004;138(1-2):173-188.
  95. Kakiuchi C, Ishiwata M, Kametani M, Nelson C, Iwamoto K, Kato T. Quantitative analysis of mitochondrial DNA deletions in the brains of patients with bipolar disorder and schizophrenia. Int J Neuropsychopharmacol 2005;8(4):515-522.
  96. Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry 2004;55(7):676-684.
  97. Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, Casaccia P, Haroutunian V, Byne W. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr Res 2012;120(1-3):150-158.
  98. Kim HK, Tyryshkin K, Elmi N, et al. Examining redox modulation pathways in the post-mortem frontal cortex in patients with bipolar disorder through data mining of microRNA expression of datasets. 2018. J Psychiatry Research. 99: 39-49.
  99. Kim HL, Andreazza AC, Yeung PY, Isaacs-Trepanier, Young LT. Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J Psychiatry Neurosci 2014;39(4):276-285.
  100. Kim S, Cho H, Lee D, Webster MJ. Association between SNPs and gene expression in multiple regions of the human brain. Transl Psychiatry 2012;2:e113.
  101. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: An exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics 2007;8:413.
  102. Kim S, Hwang Y, Webster MJ, Lee D. Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders. Mol Psychiatry 2015.
  103. Kim S, Webster MJ. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2010;15(3):326-336.
  104. Kim S, Webster MJ. Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2011;16(4):452-461.
  105. Kim S, Zavitsanou K, Gurguis G, Webster MJ. Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database. Eur Neuropsychopharmacol 2012;22(10):683-694.
  106. Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF. Abnormalities in the cingulate gyrus in bipolar disorder and other severe psychiatric illnesses: post-mortem findings from the Stanley Foundation Neuropathology Consortium and literature review. Clin Neurosci Res 2002;2(3-4):171-181.
  107. Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF. Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CART) analysis of post-mortem prefrontal markers. Mol Psychiatry 2002;7(4):392-404.
  108. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. Molecular abnormalities of the hippocampus in severe psychiatric illness: post-mortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 2004;9(6):544[image],609-620.
  109. Knable MB, Barci BM, Webster MJ, Torrey EF. Summary of prefrontal molecular abnormalities in the Stanley Foundation Neuropathology Consortium. In Agam G, Belmaker RH, Everall I (eds), The Post-Mortem Brain in Psychiatric Research (Boston: Kluwer Academic Publishers, 2002).
  110. Knable MB, Torrey EF, Webster MJ, Bartko JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001;55(5):651-659.
  111. Knable MB, Webster MJ. Foreward. Brain Res Bull 2001;55(5):567-568.
  112. Knable MB. Schizophrenia and bipolar disorder: findings from studies of the Stanley Foundation Brain Collection. Schizophr Res 1999;39(2):149-152.
  113. Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch Gen Psychiatry 2003;60(3):311-319.
  114. Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic PS, Lidow MS. Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc Natl Acad Sci USA 2003;100(1):313-317.
  115. Kohen R, Dobra A, Tracy JH, Haugen E. Transcriptome profiling of human hippocampus dentate gyrus granule cells in mental illness. Transl Psychiatry 2014;4:e366.
  116. Kolomeets NS, Uranova NA. Numerical density of oligodendrocytes and oligodendrocyte clusters in the anterior putamen in major psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2020 Oct;270(7):841-850.
  117. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D, Bernstein J, Bening-Abu-Shach U, Ben-Asher E, Lancet D, Ritsner M, Navon R. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004;56(3):169-176.
  118. Korth C. Aggregated proteins in schizophrenia and other chronic mental diseases: DISC1opathies. Prion 2012;6(2):134-141.
  119. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 2001;52(1-2):101-105.
  120. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000;157(5):831-833.
  121. Kozlovsky N, Shanon-Weickert C, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G. Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm 2004;111(12):1583-1592.
  122. Krishnamurthy D, Harris L, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S, Vanattou-Saifoudine N, Leweke FM, Guest PC, Bahn S. Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry 2013;14(7):478-489.
  123. Krishnamurthy D, Levin Y, Harris LW, Umrania Y, Bahn S, Guest PC. Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 2011;11(3):495-500.
  124. Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005;78(1):87-93.
  125. Kromkamp M, Uylings HBM, Smidt MP, Hellemons AJCGM, Burbach JPH, Kahn RS. Decreased thalamic expression of the homeobox gene DLX1 in psychosis. Arch Gen Psychiatry 2003;60(9):869-874.
  126. Kubota-Sakashita M, Iwamoto K, Bundo M, Kato T. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia. Mol Brain 2014;7:5.
  127. Kuromitsu J, Yokoi A, Kawai T, Nagasu T, Aizawa T, Haga S, Ikeda K. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Gene Expr Patterns 2001;1(1):17-21.
  128. Kyosseva SV. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 2004;59:201-220.
  129. Laifenfeld D, Karry R, Grauer E, Klein E, Ben-Shachar D. ATF2, a member of the CREB/ATF family of transcription factors, in chronic stress and consequent to antidepressant treatment: animal models and human post-mortem brains. Neuropsychopharmacology 2004;29(3):589-597.
  130. Laifenfeld D, Karry R, Klein E, Ben-Shachar D. Alterations in cell adhesion molecule L1 and functionally related genes in major depression: a postmortem study. Biol Psychiatry 2005;57(7):716-725.
  131. Lake EMR, Steffler EA, Rowley CD, Sehmbi M, Minuzzi L, Frey BN, Bock NA. Altered intracortical myelin staining in the dorsolateral prefrontal cortex in severe mental illness. Eur Arch Psychiatry Clin Neurosci 2016; 267(5): 369-376.
  132. Law AJ and Deakin JFW. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 2001;12(13):2971-2974.
  133. Law AJ, Harrison PJ. The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J Psychiatr Res 2003;37(6):487-499.
  134. Leber SL, Llenos IC, Miller CL, Dulay JR3, Haybaeck J, Weis S. Homer1a protein expression in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2017; 124 (10):1261–1273.
  135. Lee FJS, Pei L, Liu F. Disruption of the dopamine transporter-dopamine D2 receptor interaction in schizophrenia [letter]. Synapse 2009;63(8):710-712.
  136. Lee S, Tsao TT, Yang KC, Lin H, Kuo YL, Hsu CH, Lee WK, Huang KC, Kao CY. Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression. BMC Bioinformatics 2011;12(Suppl 13):S20.
  1. Li, Fang, Sabunciyan S, Yolken RH, et al. Transcription of human endogenous retroviruses in human brain by RNA-seq analysis. PLOS ONE January 2019.
  2. Liu L, Schulz SC, Lee S, Reutiman TJ, Fatemi SH. Hippocampal CA1 pyramidal cell size is reduced in bipolar disorder. Cell Mol Neurobiol 2007;27(3):351-358.
  3. López-Figueroa AL, Norton CS, López-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, López JF, Watson SJ. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004;55(3):225-233.
  4. López-Figueroa AL, Watson SJ, López-Figueroa MO. [Use of the genetic chip technology to study nitric oxide synthase]. Rev Neurol 2001;33(6):555-560.
  5. Luo X-J, Mattheisen Md, Li M, et al. Systematic integration of brain eQTL and GWAS Identifies ZNF323 as a novel schizophrenia risk gene and suggests recent positive selection based on compensatory advantage on pulmonary function. Schizophr Bull 2015; 41: 1294-1308.
  6. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008;101:76-83.
  7. Maida ME, Hurley SD, Daeschner JA, Moore AH, O’Banion MK. Cytosolic prostaglandin E(2) synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res 2006;1103(1):164-172.
  8. Malki K, Keers R, Tosto MG, Lourdusamy A, Carboni L, Domenici E, Uher R, McGuffin P, Schalkwyk LC. The endogenous and reactive depression subtypes revisited: integrative animal and human studies implicate multiple distinct molecular mechanisms underlying major depressive disorder. BMC Medicine 2014;73(12).
  9. Malki K, Keers R, Tosto MG, Lourdusamy A, Carboni L, Domenici E, Uher R, McGuffin P, Schalkwyk LC. The endogenous and reactive depression subtypes revisited: integrative animal and human studies implicate multiple distinct molecular mechanisms underlying major depressive disorder. BMC Med. 2014; 12: 73.
  10. Malki K, Keers R, Tosto MG, Lourdusamy A, Carboni L, Domenici E, Uher R, McGuffin P, Schalkwyk LC. The endogenous and reactive depression subtypes revisited: integrative animal and human studies implicate multiple distinct molecular mechanisms underlying major depressive disorder. BMC Med. 2014; 12: 73.
  11. Malki K, Pain O, Tosto MG, Rietz ED, Carboni L, Schalkwyk LC. Identification of genes and gene pathways associated with major depressive disorder by integrative brain analysis of rat and human prefrontal cortex transcriptomes. Transl Psychiatry 2015;e519(5).
  12. Malki K, Tosto MG, Jumabhoy I, et al. Integrative mouse and human mRNA studies using WGCNA nominates novel candidate genes involved in the pathogenesis of major depressive disorder. Pharmacogenomics. 2013; 14: 1979-90.
  13. Manaye KF, Lei DL, Tizabi Y, Davila-Garcia MI, Mouton PR, Kelly PH. Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J Neuropathol Exp Neurol 2005;64(3):224-229.
  14. Marazziti D, Giannaccini G, Giromella A, Betti L, Pesce D, Nardi I, Rossi A, Lucacchini A, Cassano GB. [3H]-ketanserin binding sites in different psychiatric disorders. Neurochem Int 2003;42(6):511-516.
  15. Marti-Mengual U, Varea E, Crespo C, Blasco-Ibáñez JM, Nacher J. Cells expressing markers of immature neurons in the amygdala of adult humans. Eur J of Neurosci 2013;37(1):10-22.
  16. Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 2006;31(6):1249-1263.
  17. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF, Newell KA. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J Psychiatry Neurosci. 2014 Nov;39(6):407-16.
  18. Matthews PR, Eastwood SL, Harrison PJ. Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PLoS One 2012;7(6):e38211.
  19. Matthews PR, Harrion PJ. A morphometric, immunohistochemical, and in situ hybridization study of the dorsal raphe nucleus in major depression, bipolar disorder, schizophrenia, and suicide. J Affect Disord 2012;137(1-3):125-134.
  20. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002;26(3):368-375.
  21. McNamara RK, Hahn CG, Jandacek R, Rider T, Tso P, Stanford KE, Richtand NM. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 2007;62(1):17-24.
  22. McNamara RK, Rider R, Jandacek R, Tso P. Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis. Psychiatry Res 2014;215(3):560-567.
  23. Meador-Woodruff JH, Hogg AJ Jr, Smith RE. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 2001;55(5):631-640.
  24. Mei J, Kolbin D, Kao HT, Porton B. Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 2006;84(2-3):204-213.
  25. Miller CL, Dulay JR. The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res Bull 2008;77(1):33-41.
  26. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008;52(6):1297-1303.
  27. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006;1073-1074:25-37.
  28. Mimmack ML, Brooking J, Bahn S. Quantitative polymerase chain reaction: validation of microarray results from postmortem brain studies. Biol Psychiatry 2004;55(4):337-345.
  29. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RL, McKenna PJ, Jones PB, Arai H, Starkey M, Emson PC, Bahn S. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci USA 2002;99(7):4680-4685.
  30. Mistry M, Gillis J, Pavlidis P. Genome-wide expression profiling of schizophrenia using a large combined cohort. Mol Psychiatry 2013;18(2):215-225.
  31. Mueller HT, Meador-Woodruff J. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression, and bipolar disorder. Schizophr Res 2004;71(2-3):361-370.
  32. Munakata K, Iwamoto K, Bundo M, Kato T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry 2005;57(5):525-532.
  33. Nishioka M, Bundo M, Ueda J, et al. Identification of somatic mutations in postmortem human brains by whole genome sequencing and their implications for psychiatric disorders.  2018. Psychiatry and Clinical Neurosciences. 72: 280-294.
  34. Noga JT, Wang H. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse 2002;45(4):250-258.
  35. Novak G, Kim D, Seeman P, Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Molec Brain Res 2002;107(2):183-189.
  36. Novak G, Tallerico T. Nogo A, B, and C expression in schizophrenia, depression and bipolar frontal cortex and correlation of Nogo expression with cAA/TATC polymorphism in 3’-UTR. Brain Res 2006;1120(1):161-71.
  37. Nudmamud S, Reynolds LM, Reynolds GP. N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol Psychiatry 2003;53(12):1138-1141.
  38. Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004;372(1-2):173-177.
  39. O’Connor JA, Hemby SE. Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia. Schizophr Res 2007;97(1-3):277-288.
  40. O’Connor JA, Muly EC, Arnold SE, Hemby SE. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs. Schizophr Res 2007;90(1-3):28-40.
  41. Oh DH, Oh D, Son H, Webster M, Weickert CS, Kim SH. An association between the reduced levels of SLC1A2 and GAD1 in the dorsolateral prefrontal cortex in major depressive disorder: possible involvement of an attenuated RAF/MEK/ERK signaling pathway. J Neural Transm. 2014;121(7):783-792.
  42. Oh DH, Park YC, Kim SH. Increased glycogen synthase kinase-3β mRNA level in the hippocampus of patients with major depression: a study using the Stanley Neuropathology Consortium Integrative Database. Psychiatry Investig 2010;7(3):202-207.
  43. Oh DH, Son H, Hwang S, Kim SH. Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder. Eur Neuropsychopharmacol 2012;22(5):330-338.
  44. Oh DH, Son H, Hwang S, Kim SH. Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder. Eur Neuropsychopharmacol 2012;22(5):330-338.
  45. Oh G, Wang S-C, Pal M, et al. DNA modification study of major depressive disorder: Beyond locus-by-locus comparisons. Biol Psychiatry 2015; 77: 246-255.
  1. Okazaki S, Otsuka I, Numata S, et al. Epigenetic clock analysis of blood samples from Japanese schizophrenia patients. NPJ Schizophrenia. 2019.
  2. Oliveira RMW, Guimarães FS, Deakin JFW. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41(4):333-341.
  3. Öngür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998;95(22):13290-13295.
  4. Ottis P, Bader V, Trossbach SV, Kretzschmar H, Michel M, Leliveld SR, Korth C. Convergence of two independent mental disease genes on the protein level: recruitment of dysbindin to cell-invasive disrupted-in-schizophrenia 1 aggresomes. Biol Psychiatry 2011;70(7):604-610.
  1. Owens, SJ, Purves-Tyson, TD, Webster MJ. Evidence for enhanced androgen action in the prefrontal cortex of people with bipolar disorder but not schizophrenia or major depressive disorder. Psychiatry Research 2019
  2. Peckys D, Hurd YL. Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. Brain Res Bull 2001;55(5):619-624.
  3. Pennington K, Dicker P, Dunn MJ, Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 2008;8(23-24):5097-5107.
  4. Pennington K, Dicker P, Hudson L, Cotter DR. Evidence for reduced neuronal somal size within the insular cortex in schizophrenia, but not in affective disorders. Schizophr Res 2008;106(2-3):164-171.
  5. Perez-Santiago J, Diez-Alarcia R, Callado LF, Zhang JX, Chana G, White CH, Glatt SJ, Tsuang MT, Everall IP, Meana JJ, Woelk CH. A combined analysis of microarray gene expression studies of the human prefrontal cortex identifies genes implicated in schizophrenia. J Psychiatr Res 2012;46(11):1464-1474.
  6. Perlman WR, Tomaskovic-Crook E, Montague DM, Webster MJ, Rubinow DR, Kleinman JE, Weickert CS. Alteration in Estrogen Receptor alpha mRNA Levels in Frontal Cortex and Hippocampus of Patients with Major Mental Illness. Biol Psychiatry 2005;58(10):812-824.
  7. Perlman WR, Webster MJ, Kleinman JE, Weickert CS. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry 2004;56(11):844-852.
  8. Pidsley R, Dempster E, Troakes C, Al-Sarraj S, Mill J. Epigenetic and genetic variation at the IGF2/H19 imprinting control region on 11p15.5 is associated with cerebellum weight. Epigenetics 2012;7(2):155-163.
  9. Pidsley R, Dempster EL, Mill J. Brain weight in males is correlated with DNA methylation at IGF2 [letter]. Mol Psychiatry 2010;15(9):880-881.
  10. Polesskaya OO, Aston C, Sokolov BP. Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1J Neurosci Res 2006;83(3):362-373.
  11. Polesskaya OO, Haroutunian V, Davis KL, Hernandez I, Sokolov BP. Novel putative nonprotein-coding RNA gene from 11q14 displays decreased expression in brains of patients with schizophrenia. J Neurosci Res 2003;74(1):111-122.
  12. Polesskaya OO, Sokolov BP. Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002;67(6):812-822.
  13. Porton B, Wetsel WC. Reduction of synapsin III in the prefrontal cortex of individuals with schizophrenia. Schizophr Res 2007;94(1-3):366–370.
  14. Prusty BK, Gulve N, Govind S, et al. Active HHV-6 infection of cerebellar Purkinje cells in Mood Disorders. Frontiers in Microbiology. 2018.  doi: 10.3389/fmicb.2018.01955.
  15. Puthumana JS, Regenold WT. Glucose-6-phosphate dehydrogenase activity in bipolar disorder and schizophrenia: Relationship to mitochondrial impairment. 2019. J Psychiatric Research. 112: 99-103.
  16. Qian K, Di Lieto A, Corander J, Auvinen P, Greco D. Re-analysis of bipolar disorder and schizophrenia gene expression complements the Kraepelinian dichotomy. Adv Exp Med Biol 2012;736:563-77.
  17. Rathje M, Waxman H, Benoit M, et al. Genetic variants in the bipolar disorder risk locus SYNE1 that affect CPG2 expression and protein function. 2019. Mol Psychiatry.
  18. Ray MT, Weickert CS, Wyatt EW, Webster MJ. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2001;36(3):195-203.
  19. Ray MT, Weickert SC, Webster MJ. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Trans Psychiatry 2014;4:e389.
  20. Regenold WT, Phatak P, Kling MA, Hauser P. Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders [letter]. Mol Psychiatry 2004;9(8):731-733.
  21. Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res 2007;151(3):179-188.
  22. Regenold WT, Pratt M, Nekkalapu S, Shapiro PS, Kristian T, Fiskum G. Mitochondrial detachment of hexokinase 1 in mood and psychotic disorders: implications for brain energy metabolism and neurotrophic signaling. J Psyc Res 2012;46(1):95-104.
  23. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, Lesch KP. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006;11(5):514-522.
  24. Reynolds GP, Beasley CL, Zhang ZJ. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J Neural Transm 2002;109(5-6):881-889.
  25. Reynolds GP, Zhang ZJ, Beasley CL. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Res Bull 2001;55(5):579-584.
  26. Rosenfeld M, Brenner-Lavie H, Ari SG, Kavushansky A, Ben-Shachar D. Perturbation in mitrochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry 2011;69(10):980-988.
  27. Ruzicka WB, Zhubi A, Veldic M, Grayson DR, Costa E, Guidotti A. Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol Psychiatry 2007;12(4):385-397.
  28. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 2006;11(10):965-978.
  29. Sabunciyan S, Kirches E, Krause G, Bogerts B, Mawrin C, Llenos IC, Weis S. Quantification of total mitochondrial DNA and mitochondrial common deletion in the frontal cortex of patients with schizophrenia and bipolar disorder. J Neural Transm 2007;114(5):665-674.
  30. Sabunciyan S, Yolken R, Ragan CM, Potash JB, Nimgaonkar VL, Dickerson F, Llenos IC, Weis S. Polymorphisms in the homeobox gene OTX2 may be a risk factor for bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B:1083–1086.
  31. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007;7:46.
  32. Schramm M, Falkai P, Feldmann N, Knable MB, Bayer TA. Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia. Neurosci Lett 1998;257(2):65-68.
  33. Schramm M, Falkai P, Tepest R, et al. Stability of RNA transcipts in post-mortem psychiatric brains. J Neural Transm (Vienna). 1999; 106: 3-4.
  34. Seifuddin F, Pirooznia M, Judy JT, Goes FS, Potash JB, Zandi PP. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry 2013;13:213.
  35. Selemon LD, Begovic A. Stereologic analysis of the lateral geniculate nucleus of the thalamus in normal and schizophrenic subjects. Psychiatry Res 2007;151(1-2):1-10.
  36. Seredenina T, Sorce S, Herrmann FR, Ma Mulone XJ, Plastre O, Aguzzi A, Jaquet V, Krause KH. Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse. Transl Psychiatry. 2017 Aug; 7(8): e1206.
  37. Shaltiel G, Kozlovsky N, Belmaker RH, Agam G. 3′(2′)-phosphoadenosine 5′-phosphate phosphatase is reduced in postmortem frontal cortex of bipolar patients. Bipolar Disord 2002;4(5):302-306.
  38. Shaltiel G, Shamir A, Nemanov L, Yaroslavsky Y, Nemets B, Ebstein RP, Belmaker RH, Agam G. Inositol monophosphatase activity in brain and lymphocyte-derived cell lines of bipolar patients. World J Biol Psychiatry 2001;2(2):95-98.
  39. Shamir A, Elhadad N, Belmaker RH, Agam G. Interaction of calbindin D28k and inositol monophosphatase in human postmortem cortex: possible implications for bipolar disorder. Bipolar Disord 2005;7(1):42-48.
  40. Shamir A, Shaltiel G, Levi I, Belmaker RH, Agam G. Postmortem parietal cortex TPH2 expression is not altered in schizophrenic, unipolar-depressed, and bipolar patients vs control subjects. J Mol Neurosci 2005;26(1):33-38.
  41. Shapiro J, Belmaker RH, Biegon A, Seker A, Agam G. Scyllo-inositolin post-mortem brain of bipolar, unipolar and schizophrenic patients. J Neural Transm 2000;107(5):603-607.
  42. Simmons M, Meador-Woodruff JH, Sodhi MS. Increased cortical expression of an RNA editing enzyme occurs in major depressive suicide victims. Neuroreport 2010;21(15):993-997.
  43. Skoblenick KJ, Castellano JM, Rogoza RM, Dyck BA, Thomas N, Gabriele JP, Chong VZ, Mishra RK. Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment. Apoptosis 2006;11(5):663-672.
  44. Smalheiser NR, Lugli G, Zhang H, Rizavi H, Cook EH, Dwivedi Y. Expression of micro RNAs and other small RNAs in prefrontal cortex in schizophrenia, bipolar disorder and depressed subjects. PLoS One 2014;9(1):e86469.
  45. Smolin B, Karry R, Gal-Ben-Ari S, Ben-Shachar D. Differential expression of genes encoding neuronal ion-channel subunits in major depression, bipolar disorder and schizophrenia: implications for pathophysiology. Int J Neuropsychopharmacol 2012;15(7):869-882.
  46. Sokolov BP, Jiang L, Trivedi NS, Aston C. Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. J Neurosci Res 2003;72(6):756-767.
  47. Sokolov BP. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol 2007;10(4):547–555.
  48. Soontornniyomkij B, Everall IP, Chana G, Tsuang MT, Achim CL, Soontornniyomkij V. Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder. J Affect Disord 2011;133(3):646-654.
  49. Stelzhammer V, Alsaif M, Chan MK, Rahmoune H, Steeb H, Guest PC, Bahn S. Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. J Psychiatr Res 2015;60:40-48.
  50. Stewart RJ, Chen B, Dowlatshahi D, MacQueen GM, Young LT. Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Res Bull 2001;55(5):625-629.
  51. Struyf J, Dobrin S, Page D. Combining gene expression, demographic and clinical data in modeling disease: a case study of bipolar disorder and schizophrenia. BMC Genomics 2008;9:531.
  52. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. 2006. Science.  311: 77-80.
  53. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ, Trojanowski JQ, Gur RE, Blake DJ, Arnold SE. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004;113(9):1353-1363.
  54. Tatebayashi Y, Nihonmatsu-Kikuchi N, Hayashi Y, Yu X, Soma M, Ikeda K. Abnormal fatty acid composition in the frontopolar cortex of patients with affective disorders. Translational Psychiatry 2012;2:e204.
  55. Thakker-Varia S, Jean YY, Parikh P, Sizer CF, Jernstedt Ayer J, Parikh A, Hyde TM, Buyske S, Alder J. The Neuropeptide VGF is reduced in human bipolar postmortem brain and contributes to some of the behavioral and molecular effects of lithium. J Neurosci 2010;30(28):9368-9380.
  56. Thomas AJ, Davis S, Ferrier IN, Kalaria RN, O’Brien JT. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 2004;55(6):652-655.
  57. Thompson M, Weickert CS, Wyatt E, Webster M. Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res 2009;43(11):970-977.
  58. Thompson RM, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK+ and GAD(67) mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011;36(1):100048 [Epub ahead of print].
  59. Thomsen MS, Weyn A, Mikkelsen JD. Hippocampal α7 nicotine acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disord 2011;13(7-8):701-707.
  60. Tian SY, Wang JF, Bezchlibnyk YB, Young LT. Immunoreactivity of 43 kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia. Neurosci Lett 2007;411(2):123-127.
  61. Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol 2007;10(4):557–563.
  62. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003;362(9386):798-805.
  63. Tochigi M, Iwamoto K, Bundo M, Komori A, Sasaki T, Kato N, Kato T. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry 2008;63(5):530-533.
  64. Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, Kato T. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res 2008;60(2):184-191.
  65. Tomasik J. Virus discovery analyses on post-mortem brain tissue and cerbrospinal fluid of schizophrenia patients. Schizophr Res. 2018; 197: 605-606.
  66. Toro C, Deakin JFW. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 2005;80(2-3):323-330.
  67. Toro CT, Hallak JEC, Dunham JS, Deakin JFW. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 2006;404(3):276-281.
  68. Torrell H, Montana E, Abasolo N, Roig B, Gaviria AM, Vilella E, Martorell L. Mitochondrial DNA (mtDNA) in brain samples from patients with major psychiatric disorders: gene expression profiles, MtDNA content and presence of the MtDNA common deletion. Am J Med Genet B Neuropsychiatr Genet 2013; 162B(2):213-23.
  69. Torrey EF, Barci BM, Bartko JJ, Webster MJ, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005;57(3):252-260.
  70. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000;44(2):151-155.
  71. Tunbridge E, Burnet PW, Sodhi MS, Harrison PJ. Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse 2004;51(2):112-118.
  72. Tyekucheva S, Yolken RH, McCombie WR, Parla J, Kramer M, Wheelan SJ, Sabunciyan S. Establishing the baseline level of repetitive element expression in the human cortex. BMC Genomics 2011;12:495.
  73. Ubhi K, Price J. Expression of POU-domain transcription factor, Oct-6, in schizophrenia, bipolar disorder and major depression. BMC Psychiatry 2005;5:38.
  74. Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord 2009;11(7):711-725.
  75. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004;67(2-3):269-275.
  76. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007;10(4):537–545.
  77. Varea E, Guirado R, Gilabert-Juan J, Martí U, Castillo-Gomez E, Blasco-Ibáñez JM, Crespo C, Nacher J. Expression of PSA-NCAM and synaptic proteins in the amgydala of psychiatric disorder patients. J Psychiatr Res 2012;46(2):189–197.
  78. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH III, Donovan DM, Webster M, Freed WJ, Becker KG. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 2001;55(5):641-650.
  79. Veldman ER, Svedberg MM, Svenningsson P,  Ludberg J. Distribution and levels of 5-HT1b receptors in anterior cingulate cortex of patents with bipolar disorder, major depressive disorder and schizophrenia—An autoradiography study. 2017. European Neuropsychopharmacology  27: 504-514.
  80. Vostrikov VM, Uranova NA. Reduced density of oligodendrocytes and oligodendrocyte clusters in the caudate nucleus in major psychiatric illnesses. Schizophr Res. 2020 Jan;215:211-216.
  81. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007;94(1-3):273-280.
  82. Vostrikov VM, Uranova NA. Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr Res Treatment 2011;2011:174689.
  83. Vostrikov VM, Uranova NA. Reduced density of oligodendrocytes and oligodendrocyte clusters in the caudate nucleus in major psychiatric illness. Schizophrenia Research. 2019.
  84. Walton NM, Kogan JH, Shin R, Webster M, Gross AK, Heusner CL, Chen Q, Miyake S, Tajinda K, Tamura K, Miyakawa T, Matsumoto M. Detection of an immature dentate gyrus feature in human schizophrenia/bipolar patients. Transl Psychiatry 2012;2:e135.
  85. Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009;11(5):523-529.
  86. Webster MJ, Kim S. Collecting, storing, and mining research data in a brain bank. Handb Clin Neurol 2018: 150: 167-179.
  87. Webster MJ, Knable MB, Johnston-Wilson N, Nagata K, Inagaki M, Yolken RH. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav Immun 2001;15(4):388-400.
  88. Webster MJ, Knable MB, O’Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002;7(9):985-994.
  89. Webster MJ, Knable MB, O’Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders [image]. Mol Psychiatry 2002;7(9):924.
  90. Webster MJ, O’Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005;133(2):453-461.
  91. Webster MJ, Vawter MP, Freed MJ. Immunohistochemical localization of the cell adhesion molecules Thy-1 and L1 in the human prefrontal cortex patients with schizophrenia, bipolar disorder, and depression. Mol Psychiatry 1999;4(1):46-52.
  92. Webster MJ. Tissue preparation and banking. Prog Brain Res 2006;158:3-14.Weickert CS, Webster MJ, Hyde TM, Herman MM, Bachus SE, Bali G, Weinberger DR, Kleinman JE. Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cereb Cortex 2001;11(2):136-147.
  93. Weis S, Haybaeck J, Dulay JR, Llenos IC. Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression. J Neural Transm 2008;115(5):761-771.
  94. Weis S, Llenos IC, Dulay JR, Verma N, Sabunciyan S, Yolken RH. Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J Neural Transm 2007;114(2):261-271.
  95. Weis S, Llenos IC, Sabunciyan S, Dulay JR, Isler L, Ryolken R, Perron H. Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. J Neural Transm 2007;114(5):645-655.
  96. Weis S, Llenos IC. GFAP-immunopositive astrocytes in schizophrenia. Schizophr Res 2004;67(2-3):293-295.
  97. Wong AH, Likhodi O, Trakalo J, Yusuf M, Sinha A, Pato CN, Pato MT, Van Tol HH, Kennedy JL. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr Res 2005;78(2-3):137-146.
  1. Wu C, Huang BE, Chen G, et al. Integrative analysis of DiseaseLand Omics database for disease signatures and treatments. Frontiers in Genetics 2019.
  2. Xing G, Chavko M, Zhang LX, Yang S, Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 2002;58(1):21-30.
  3. Xing G, Russell S, Hough C, O’Grady J, Zhang L, Yang S, Zhang LX, Post R. Decreased prefrontal CaMKII alpha mRNA in bipolar illness. Neuroreport 2002;13(4):501-505.
  4. Xing G, Zhang L, Russell S, Post R. Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. Schizophr Res 2006;84(1):36–56.
  5. Xing GQ, Russell S, Webster MJ, Post RM. Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 2004;7(2):143-153.
  6. Yang B, Ren Q, Zhang JC, Chen QX, Hashimoto K. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain-liver axis. Transl Psychiatry. 2017 May; 7(5): e1128.
  7. Yeo IJ, Yun J, Son DJ, et al. Overexpression of transmembrane TNFα in brain endothelial cells induces schizophrenia-relevant behaviors. Mol Psychiatry. 2022;10.1038/s41380-022-01846-7
  8. Yolken RH. Subtraction libraries for the molecular characterization of gene-environmental interactions in bipolar disorder. Bipolar Disord 2002;4(suppl 1):77-80.
  9. Young KA, Bonkale WL, Holcomb LA, Hicks PB, German DC. Major depression, 5HTTLPR genotype, suicide and antidepressant influences on thalamic volumes. Br J Psychiatry 2008;192(4):285-289.
  10. Young KA, Holcomb LA, Bonkale WL, Hicks PB, Yazdani U, German DC. 5HTTLPR polymorphism and enlargement of the pulvinar: unlocking the backdoor to the limbic system. Biol Psychiatry 2007;61(6):813-818.
  11. Young KA, Holcomb LA, Yazdani U, Hicks PB, German DC. Elevated neuron number in the limbic thalamus in major depression. Am J Psychiatry 2004;161(7):1270-1277.
  12. Young KA, Manaye KF, Liang C, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 2000;47(11):944-953.
  13. Young LT, Bezchlibnyk YB, Chen B, Wang JF, MacQueen GM. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide and drug treatment. Biol Psychiatry 2004;55(6):570-577.
  14. Yun H-M, Park K-R, Kim E-C, et al. Serotonin 6 receptor controls Alzheimer’s disease and depression. Onctotarget 2015; 29: 26716.
  15. Zavitsanou K, Katsifis A, Mattner F, Huang XF. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004;29(3):619-625.
  16. Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 2005;65(5):397-403.
  17. Zhang Z, Sun J, Reynolds GP. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chin Med J (Engl) 2002;115(6):819-823.
  18. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002;55(1-2):1-10.
  19. Zhao Z, Webb BT, Jia P, Bigdeli TB, Maher BS, van den Oord E, Bergen SE, Amdur RL, O’Neill FA, Walsh D, Thiselton DL, Chen X, Pato CN; International Schizophrenia Consortium, Riley BP, Kendler KS, Fanous AH. Association study of 167 candidate genes for schizophrenia selected by a multi-domain evidence-based prioritization algorithm and neurodevelopmental hypothesis. PLoS One 2013;6(7):e67776.